Loading stock data…
Anixa Biosciences, Inc. (ANIX)
$3.07+0.02 (+0.66%)
Pre-Market$3.28+0.21 (+6.84%)· Last close Sep 4
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Anixa Biosciences, Inc. in the Healthcare sector is trading at $3.07 with a market capitalization of $111M. Wall Street consensus targets $10.00 (4 analysts), implying a +225.7% move over the next 12 months. The stock is currently 44% below its 52-week high of $5.46, remaining 2.8% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +225.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 34) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$2.65M↑ | -$2.72M↑ | -$2.88M↓ | -$2.44M↑ | -$3.00M |
| Net Income | -$2.52M↑ | -$2.56M↑ | -$2.69M↓ | -$2.26M↑ | -$2.79M |
Peer Comparison
JNJUNHPFE
Fundamentals
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T ce...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$111.26M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.60
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-69.32%
Volume
Today's trading volume
368,209
Recent News
Anixa Biosciences (ANIX) Upgraded to Strong Buy: Here's What You Should Know
Anixa Biosciences (ANIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?
Here is how Allarity Therapeutics, Inc. (ALLR) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.
New Strong Buy Stocks for July 22nd
HTLD, YEXT, ANIX, WVE and LCNB have been added to the Zacks Rank #1 (Strong Buy) List on July 22, 2026.
Anixa Biosciences secures Korean patent for breast cancer vaccine
The patent expands Anixa’s IP portfolio beyond the US and existing international markets.
Here's Why You Should Add ANIX Stock to Your Portfolio Now
Anixa advances cancer vaccines and CAR-T therapies, supported by positive early data, a planned phase II study and expanding intellectual property protection.